Johnson & Johnson (NYSE:JNJ) Shares Bought by Meeder Advisory Services Inc.

Meeder Advisory Services Inc. increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 37,359 shares of the company’s stock after purchasing an additional 882 shares during the quarter. Meeder Advisory Services Inc.’s holdings in Johnson & Johnson were worth $5,403,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. IFS Advisors LLC grew its holdings in shares of Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after purchasing an additional 100 shares during the last quarter. WealthTrak Capital Management LLC bought a new position in Johnson & Johnson during the 4th quarter worth $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson in the fourth quarter worth $29,000. Bay Harbor Wealth Management LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at $32,000. Finally, Runnymede Capital Advisors Inc. acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $38,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 7.6 %

Shares of NYSE:JNJ opened at $153.25 on Wednesday. The stock has a market capitalization of $369.30 billion, a price-to-earnings ratio of 23.04, a PEG ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a 50 day moving average price of $159.16 and a 200 day moving average price of $155.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period in the previous year, the firm earned $2.29 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.3% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.24%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 10th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Stifel Nicolaus decreased their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Finally, Raymond James decreased their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.